Sijia Cai
Lawyers
Filters
Aptiv $2.2 billion ordinary share and mandatory convertible preferred offerings
Davis Polk advised Aptiv PLC in connection with a $1.1 billion SEC-registered offering of 15,149,519 ordinary shares (which included 1,976,024 ordinary shares that the underwriters…
Alector $150 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …
Morgan Stanley $3 billion SOFR fixed-to-floating-rate senior notes offering
Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $3 billion aggregate principal amount of fixed-to-floating-rate senior notes due 2026. During the…
Mitsubishi UFJ Lease & Finance $800 million senior notes offering
Davis Polk advised Mitsubishi UFJ Lease & Finance Company Limited on its Rule 144A/Regulation S offering of senior notes, which consisted of $450 million aggregate principal amount of 3…
Morgan Stanley $3 billion fixed-to-floating-rate (SOFR) senior notes offering
Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $3 billion aggregate principal amount of fixed-to-floating-rate senior notes due 2031. During the…
NVIDIA $5 billion notes offering
Davis Polk advised the sole underwriter in connection with a $5.0 billion SEC-registered notes offering by NVIDIA Corporation, consisting of $1.5 billion aggregate principal amount of…
Morgan Stanley $2 billion offering of fixed-to-floating-rate (SOFR) senior notes
Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $2 billion aggregate principal amount of fixed-to-floating rate senior notes due 2051. During the…
Revolution Medicines $273.7 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…
Theravance Biopharma $148.5 million follow-on offering
Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…
Morgan Stanley C$1 billion senior notes offering
Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of CAD1 billion aggregate principal amount of floating-rate senior notes due 2023. The notes, which…